Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The document concludes that various treatments for skin conditions are effective, but some require further research, and certain factors like gender and lifestyle can influence disease outcomes.

There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.

This review discusses the mechanism and side effects of smoothened inhibitors for advanced basal cell carcinoma, reporting no new clinical results and highlighting current management strategies for these adverse events.

In this study, mice exposed to prolonged space conditions demonstrated skin atrophy, altered hair follicle cycles, and significant changes in the gene expression associated with skin muscle health.

This case study found that a multimodal treatment approach effectively improved hair density and scalp coverage in a patient with androgenetic alopecia, with no reported adverse effects.

This study examined interactions between immune cells and dermal papilla cells in a patient with alopecia areata using single-cell RNA sequencing; it identified specific T cell subtypes and ligand-receptor pairs that may contribute to hair cycle disruption through inflammation.

In this study, increased corticosterone from chronic stress prolonged hair follicle stem cell quiescence in mice, inhibiting regeneration, but restoring Gas6 expression overcame this inhibition.

This study presents evidence that specific thymus-derived peptides affect human hair follicle growth, identifying thymulin as a potential hair growth stimulator despite interindividual response variations.

This study found that platelet-rich plasma therapy increased hair density in androgenetic alopecia and improved hair regrowth in chronic plaque alopecia, with better results when combined with minoxidil rather than finasteride.

In this study, stress hormone CRF was found to inhibit hair growth, suggesting that the HPA axis is functional in human dermal papilla cells and contributes to hair loss under stress conditions.

This study found that ocu-miR-205 promotes changes in signaling pathways and shifts in hair follicle phases, affecting Rex rabbit hair density by increasing secondary follicles.

This study showed that the stress hormone CRF inhibits hair growth and induces hair loss by affecting both the proliferation of human dermal papilla cells and hair follicle function.

This study found that prolactin and its receptor are expressed in the murine hair follicle epithelium, influencing hair cycle phases by down-regulating keratinocyte proliferation during anagen and inducing premature catagen.

This study found that Notch-related genes, including Notch1 and Notch2, and their ligands and regulators, have distinct patterns of expression during mouse hair vibrissa follicle development and the adult hair cycle.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This study found that a spermidine-based nutritional supplement increased the number of anagen phase hair follicles in healthy humans, suggesting potential benefits for hair loss conditions.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This study found that using minoxidil 2% as a mesotherapy injection showed more significant improvement in treating androgenetic alopecia in female patients than topical application.

This study found that while MK-0773 significantly increased lean body mass in sarcopenic frail elderly women, it did not significantly improve muscle strength or physical function compared to placebo.

This study suggests that applying topical Tempol to the scalp before whole brain radiation may protect against radiation-induced alopecia and is safe and well-tolerated.

This article discusses SARS-CoV-2-induced telogen effluvium in a multicentric study and reports no new clinical results.

In this study, the authors concluded that COVID-19 may not cause direct long-term harm to testicular function, but temporary indirect effects could occur, suggesting a possible delay in pursuing parenthood post-recovery.

This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.

This article reviews finasteride's potential side effects, notably post-finasteride syndrome, and suggests that hand preference and sexual orientation might predict these adverse effects, but it reports no clinical results.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This study found that PRP injections may safely improve penile curvature and PDQ scores in men with stable-phase Peyronie's Disease, although the curvature reduction observed was not enough to determine long-term clinical significance.

In this research, a new cream containing salicylic acid was developed to treat acne vulgaris, showing no allergic reactions or skin irritation and maintaining stability in controlled conditions, suggesting potential future benefits for skin care and anti-acne treatment.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

This study found that both 0.01% and 0.03% bimatoprost gel and 2% minoxidil gel significantly improved eyebrow density in individuals with hypotrichosis, with no significant difference between the treatments, although the highest bimatoprost concentration showed a more favorable response.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.